Activated t cells and their use in treating cancer

CN115246887BActive Publication Date: 2026-08-28FOSHAN HEAT SHOCK BIOTECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202110460180.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-04-27
Publication Date
2026-08-28
Estimated Expiration
2041-04-27

AI Technical Summary

Benefits of technology

[0099]“胰腺癌”：是恶性程度极高的消化道肿瘤之一，其在全球的发病率和死亡率均在逐年升高。目前临床上治疗胰腺癌的方式主要包括手术切除、放化疗。由于胰腺癌发病隐匿、病情进展快、恶性程度高等特点，患者一经发现多处于癌症的中晚期，丧失手术机会，导致患者5年生存率不足6％。为延长患者生存时间，积极探索有效的治疗方法是目前胰腺癌治疗领域亟待解决的问题。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115246887B_ABST
    Figure CN115246887B_ABST
Patent Text Reader

Abstract

The present application relates to activated T cells and their use in the treatment of cancer. In particular, the present application relates to a T cell activated by a placental derived heat shock protein gp96-antigen complex, and pharmaceutical compositions containing said T cells and their use against tumors.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Epitope peptide of GPNMB and compound of epitope peptide and heat shock protein

    CN115490765A